Four technology appraisals (TAs) have been published by NICE, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:

TA455—Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

TA456—Ustekinumab for moderately to severely active Crohn’s disease after previous treatment

TA457—Carfilzomib for previously treated multiple myeloma

TA458—Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane*

*This guidance is a Cancer Drugs Fund reconsideration of Trastuzumab emtansine for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371). This guidance replaces TA371.

NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.